Figures computed from official regulatory filings — .
Analysttarget 9.5 USD (+137%) · consensus 4.11/5 · 6 buy · 3 hold · 0 sell
Ownershipinsiders 4.47% · institutions 72% · short 8.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BICYCLE THERAPEUTICS PLC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
18 buys240 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Hannay Michael Charles Ferguson | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Thompson Travis Alvin | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Perry Jennifer Scott | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Skynner Michael | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hannay Michael Charles Ferguson | Sell | $1.1K | SEC |
| Hannay Michael Charles Ferguson | Sell | $6.4K | SEC |
| Thompson Travis Alvin | Sell | $3.5K | SEC |
| Lee Kevin | Sell | $25.2K | SEC |
| Perry Jennifer Scott | Sell | $185.3 | SEC |
| Skynner Michael | Sell | $2.3K | SEC |
| Skynner Michael | Sell | $7.9K | SEC |
| Perry Jennifer Scott | Sell | $4.4K | SEC |
| Perry Jennifer Scott | Sell | $1.4K | SEC |
| Lee Kevin | Sell | $7.5K | SEC |
| Thompson Travis Alvin | Sell | $448.2 | SEC |
| Lee Kevin | Sell | $29.3K | SEC |
| Perry Jennifer Scott | Sell | $186.9 | SEC |
| Skynner Michael | Sell | $2.7K | SEC |
| Skynner Michael | Sell | $9.2K | SEC |
| Thompson Travis Alvin | Sell | $515.1 | SEC |
| Perry Jennifer Scott | Sell | $5.1K | SEC |
| Hannay Michael Charles Ferguson | Sell | $7.5K | SEC |
| Lee Kevin | Sell | $8.7K | SEC |
| Thompson Travis Alvin | Sell | $3.9K | SEC |
| Perry Jennifer Scott | Sell | $1.7K | SEC |